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Abstract: A case is reported in which docetaxel was used to treat a patient with hormone refractory metastatic prostate cancer. The 
  treatment was terminated at the third course of docetaxel following the development of hemorrhagic cystitis. This reaction was 
  unexpected, as it is not a known reaction to docetaxel. Hemorrhagic cystitis has been associated with cyclophosphamide, where the 
metabolite acrolein has been implicated. The mechanism of this reaction from docetaxel is not yet known.
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Introduction
Hemorrhagic cystitis is a serious complication which 
can occur in patients undergoing treatment for cancer. It 
is commonly known to be associated with oxazaphos-
phorine alkylating agents such as   cyclophosphomide 
and  ifosphomide,  where  the  metabolite  acrolein  is 
implicated.1 It has also been reported following dac-
arbazine  and  temozolamide  administrations.2  This 
adverse effect has also been observed in about 5% of 
patients who received   radiotherapy to the pelvis.3
Docetaxel is a semi-synthetic taxol derived from 
the needles of the yew tree. It has been used in the 
treatment of several malignancies like breast cancer, 
lung cancer, gastric cancer, head and neck cancers, 
and  prostate  cancer.4  Docetaxel  acts  by  inhibiting 
microtubule formation and as a poison to the mitotic 
spindle. The drug is metabolized in the liver to its 
hydroxylated  metabolite—cyclized  oxalozolidin-
edione (M4)5—and about 75% of the metabolites are 
excreted via bile or the faecal route while less than 
10% clearance is via the kidneys. Less than 10% of 
the drug is eliminated as the parent compound.6 The 
common side-effects following docetaxel adminis-
tration  include  neutropenia,  anaemia,  thrombocy-
topenia,  hypersensitivity  reactions,  fluid  retention 
and changes to the nails.7
Hemorrhagic cystitis is a potentially life-threatening 
side-effect seen in about 6% of patients on alky-
lating  agents  like  cyclophosphamide  and  ifosph-
amide, where it is linked to the metabolite acrolein. 
It  has  also  been  associated  with  non-steroidal 
anti-inflammatory drugs (NSAIDS),8 penicillin and 
methicillin.9 Hemorrhagic cystitis is not a known 
reaction to docetaxel.
case Report
A  73-year-old  patient  had  radical  prostatectomy 
and  bilateral  orchidectomy  for  prostate  cancer. 
Three  years  later,  he  developed  bony  metastasis 
within the pelvic bones. The patient was prepared 
for  chemotherapy.  Full  blood  count,  liver function 
tests, serum electrolytes, urea creatinine and calcium 
were within normal limits. His prostate specific anti-
gen was 20 ng/ul. The chest x-ray was not remark-
able and the abdominopelvic ultrasound revealed a 
normal bladder. The involvement of the pelvic bones 
was confirmed by a plain x-ray of the pelvis and by a 
Technisium99 bone scan.
The patient was started on docetaxel 75 mg/m2 
with oral prednisolone 5 mg twice daily   continuously 
according to protocol and was on a three-week cycle. 
Premedication  was  with  oral  dexamethazone,  with 
8 mg taken 12 h, 3 h and 1 h before the docetaxel 
infusion which was given over 70 minutes.   Antacids 
(polycrol gel) were given with the prednisolone and 
thepatient  also  received  intravenous  ondansetron 
(8  mg)  before  the  docetaxel  infusion. A  day  after 
the third cycle, the patient developed gross haema-
turia  with  mild  dysuria.  Urinalysis  confirmed  the 
  haematuria, but urine microscopy and culture did not 
yield any growth. The full blood count was within 
normal  limits. An  ultrasound  of  the  abdomen  and 
pelvis revealed slight mucosal thickening within the 
bladder with no definite mass.
The patient was managed conservatively with con-
tinuous bladder drainage and increased fluid intake. 
The  haematuria  reduced  in  intensity  and  finally 
stopped  after  two  weeks. The  packed  cell  volume 
reduced from 34% to 28% while other blood cells 
were still within normal limits. No blood transfusion 
was required. Docetaxel was discontinued and pallia-
tive radiotherapy treatment was given to the pelvic 
bones with a dose of 25Gray in 10 fractions within 
2  weeks.  He  was  also  placed  on  zelodronic  acid 
4 mg every four weeks. The patient was still alive 
six months after treatment.
Discussion
Docetaxel  is  used  either  singly  or  in  combination 
with other agents in the treatment of various malig-
nancies.  In  combination  with  prednisolone,  it  has 
been shown to prolong survival in hormone refrac-
tory metastatic prostate cancer better than mitozan-
throne and prednisolone therapy, hence its choice in 
this condition. The recommended dose in the treat-
ment  of  prostate  cancer  is  75  mg/m2  every  three 
weeks for four courses with oral prednisolone 5 mg 
twice daily continuously. The recommended premed-
ication is 8 mg oral dexamethazone taken 12 h, 3 h 
and 1 h before docetaxel infusion.10 Acrolein, which 
is associated with hemorrhagic cystis from alkylat-
ing agents like cyclophosphamide, is not a known 
metabolite of docetaxel and our patient was not on 
any other agent known to produce a predisposition 
to hemorrhagic   cystitis immediately before or during 
docetaxel therapy.Docetaxel and hemorrhagic cystitis
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The Naranjo Adverse Drug Reaction   Probability 
scale11 was used to score this drug reaction. Based on 
the objective assessment using the scale, the   resultant 
score classifies docetaxel as a   ‘probable’ cause of hem-
orrhagic cystitis in this patient. Hemorrhagic   cystitis 
is an inflammatory reaction caused by a complex pro-
cess which involves kinins,   cyclooxygenases, inter-
leukins, free radicals and other intracellular reactive 
oxygen species.   Acrolein, the metabolite of oxaza-
phosphorins, can initiate this inflammatory process.12 
Docetaxel may have a yet-to-be-identified metabolite 
that triggered off this reaction in our patient. An aller-
gic or immunological mechanism has also been sug-
gested as being responsible for the development of 
hemorrhagic cystitis.13
Another  explanation  for  the  occurrence  of  this 
  phenomenon in this patient is that there could have 
been  gradual  build-up  of  immunological  response 
against the previous two doses of the agent, which 
became more serious with the third dose, resulting in 
hemorrhagic cystis.
conclusion
This is the first report which shows that docetaxel 
at conventional doses for hormone refractory meta-
static prostate cancer is associated with hemorrhagic 
cystitis. Clinicians should be alert to the possibil-
ity of this side-effect in some patients and further 
studies are needed to identify the mechanism of this 
association.
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